NATCOPHARM Q1 FY27 results at a glance
NATCO PHARMA LTD. Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹735 cr |
|---|
| Revenue YoY | -44.7% |
|---|
| Operating profit | ₹139 cr |
|---|
| Operating margin | 19.0% |
|---|
| Net profit | ₹207 cr |
|---|
| Net profit YoY | -57.0% |
|---|
| Net profit QoQ | -22.9% |
|---|
| Net margin | 28.1% |
|---|
| Basic EPS | ₹11.53 |
|---|
| TTM revenue | ₹3,485 cr |
|---|
| TTM net profit | ₹1,144 cr |
|---|
| TTM net margin | 32.8% |
|---|
NATCOPHARM Q1 FY27 results: what the numbers say
NATCO PHARMA LTD. (NATCOPHARM) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹735 cr and a net profit of ₹207 cr, translating into earnings per share of ₹11.53.
Compared with the same quarter a year earlier, revenue declined strongly by -44.7% and net profit declined sharply by -57.0%. Profit trailing revenue growth suggests costs, interest or tax absorbed part of the topline gain.
Operating profit for the quarter stood at ₹139 cr, an operating margin of 19.0% versus 38.6% a year ago — a contraction of 19.7 percentage points.
NATCOPHARM quarter-wise results table
Net profit
₹207 cr
-57.0% YoY
Operating profit
₹139 cr
-72.8% YoY
NATCO PHARMA LTD. (NATCOPHARM) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹735 cr | ₹139 cr | ₹207 cr | 19.0% | 28.1% | ₹11.53 | -57.0% | -22.9% |
| Q4 FY262026-03-31 | ₹739 cr | ₹77.2 cr | ₹268 cr | 10.4% | 36.2% | ₹14.96 | — | +76.8% |
| Q3 FY262025-12-31 | ₹647 cr | ₹113 cr | ₹152 cr | 17.4% | 23.4% | ₹8.46 | — | -70.8% |
| Q2 FY262025-09-30 | ₹1,363 cr | ₹527 cr | ₹518 cr | 38.7% | 38.0% | ₹28.94 | — | +7.8% |
| Q1 FY262025-06-30 | ₹1,329 cr | ₹513 cr | ₹481 cr | 38.6% | 36.2% | ₹26.84 | — | — |
| TTM (last 4 quarters) | ₹3,485 cr | ₹856 cr | ₹1,144 cr | 24.6% | 32.8% | ₹63.89 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
NATCOPHARM quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
NATCO PHARMA LTD. quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹735 cr | ₹739 cr | ₹647 cr | ₹1,363 cr | ₹1,329 cr |
|---|
| Total expenses | ₹596 cr | ₹662 cr | ₹535 cr | ₹836 cr | ₹816 cr |
|---|
| Gross profit | ₹588 cr | ₹584 cr | ₹514 cr | ₹1,193 cr | ₹1,096 cr |
|---|
| Operating profit (EBIT) | ₹139 cr | ₹77.2 cr | ₹113 cr | ₹527 cr | ₹513 cr |
|---|
| Operating margin | 19.0% | 10.4% | 17.4% | 38.7% | 38.6% |
|---|
| Interest cost | ₹13 cr | ₹10.9 cr | ₹9.5 cr | ₹13.1 cr | ₹3.2 cr |
|---|
| Profit before tax | ₹186 cr | ₹144 cr | ₹161 cr | ₹614 cr | ₹572 cr |
|---|
| Tax expense | ₹63.4 cr | -₹89.2 cr | ₹20.7 cr | ₹95.8 cr | ₹91.6 cr |
|---|
| Effective tax rate | 34.2% | -61.9% | 12.8% | 15.6% | 16.0% |
|---|
| Net profit (PAT) | ₹207 cr | ₹268 cr | ₹152 cr | ₹518 cr | ₹481 cr |
|---|
| Net profit margin | 28.1% | 36.2% | 23.4% | 38.0% | 36.2% |
|---|
| Basic EPS | ₹11.53 | ₹14.96 | ₹8.46 | ₹28.94 | ₹26.84 |
|---|
| Diluted EPS | ₹11.53 | ₹14.96 | ₹8.46 | ₹28.94 | ₹26.84 |
|---|
NATCOPHARM results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | -44.7% | — | — | — | — |
|---|
| Revenue QoQ | -0.5% | +14.2% | -52.5% | +2.6% | — |
|---|
| Operating profit YoY | -72.8% | — | — | — | — |
|---|
| Operating profit QoQ | +80.6% | -31.4% | -78.6% | +2.6% | — |
|---|
| Net profit YoY | -57.0% | — | — | — | — |
|---|
| Net profit QoQ | -22.9% | +76.8% | -70.8% | +7.8% | — |
|---|
| EPS YoY | -57.0% | — | — | — | — |
|---|
| EPS QoQ | -22.9% | +76.8% | -70.8% | +7.8% | — |
|---|
NATCOPHARM annual results history
Full-year performance for NATCO PHARMA LTD., useful for reading each quarter in context.
NATCO PHARMA LTD. annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹4,045 cr | ₹4,412 cr | ₹3,979 cr | ₹2,697 cr |
|---|
| Total expenses | ₹2,788 cr | ₹2,430 cr | ₹2,402 cr | ₹1,907 cr |
|---|
| Gross profit | ₹3,123 cr | ₹3,546 cr | ₹3,116 cr | ₹1,951 cr |
|---|
| Operating profit (EBIT) | ₹1,256 cr | ₹1,981 cr | ₹1,577 cr | ₹790 cr |
|---|
| Operating margin | 31.1% | 44.9% | 39.6% | 29.3% |
|---|
| Interest cost | ₹25.8 cr | ₹17 cr | ₹12 cr | ₹9.5 cr |
|---|
| Profit before tax | ₹1,491 cr | ₹2,291 cr | ₹1,674 cr | ₹862 cr |
|---|
| Tax expense | ₹119 cr | ₹408 cr | ₹285 cr | ₹147 cr |
|---|
| Effective tax rate | 8.0% | 17.8% | 17.0% | 17.0% |
|---|
| Net profit (PAT) | ₹1,419 cr | ₹1,885 cr | ₹1,388 cr | ₹715 cr |
|---|
| Net profit margin | 35.1% | 42.7% | 34.9% | 26.5% |
|---|
| Basic EPS | ₹79.20 | ₹105.26 | ₹77.34 | ₹39.18 |
|---|
| Diluted EPS | ₹79.20 | ₹105.26 | ₹77.34 | ₹39.18 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹735 cr against ₹1,329 cr in Q1 FY26, and ₹739 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue declined -0.5%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹596 cr, or 81.0% of revenue, with operating profit declined -72.8% year on year.
Margins, tax and profitability
Net profit of ₹207 cr works out to a net margin of 28.1% compared with 36.2% in the year-ago quarter. Margin pressure of this kind usually reflects higher input costs, pricing competition, or a heavier interest and depreciation load.
Below the operating line, NATCO PHARMA LTD. reported profit before tax of ₹186 cr, a tax charge of ₹63.4 cr (effective rate 34.2%), interest cost of ₹13 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹268 cr in Q4 FY26 to ₹207 cr in Q1 FY27, a change of -22.9%.
Trailing twelve months and annual context
Across the trailing four quarters NATCO PHARMA LTD. has generated revenue of ₹3,485 cr and net profit of ₹1,144 cr, a trailing net margin of 32.8%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹4,045 cr with net profit of ₹1,419 cr and EPS of ₹79.20, versus the prior year where revenue declined -8.3% and profit declined -24.8%.
What to watch in the next NATCOPHARM quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
NATCO PHARMA LTD. has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
NATCOPHARM results coverage
No results report published for NATCOPHARM yet — our desk covers each quarter within minutes of the filing.
More on NATCOPHARM
NATCOPHARM quarterly results FAQs
What were NATCO PHARMA LTD. (NATCOPHARM) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), NATCO PHARMA LTD. reported revenue of ₹735 cr and net profit of ₹207 cr, a change of -57.0% year on year on -44.7% revenue growth. EPS stood at ₹11.53.
What is NATCOPHARM profit margin in Q1 FY27?
NATCO PHARMA LTD. posted a net profit margin of 28.1% and an operating margin of 19.0% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹3,485 cr and net profit ₹1,144 cr.
Did NATCOPHARM results beat the previous quarter?
NATCO PHARMA LTD. net profit changed -22.9% quarter on quarter, from ₹268 cr in Q4 FY26 to ₹207 cr in Q1 FY27.
When are NATCO PHARMA LTD. (NATCOPHARM) quarterly results?
NATCO PHARMA LTD. has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see NATCOPHARM latest quarterly results?
Results coverage for NATCOPHARM will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the NATCOPHARM stock page.
What is NATCO PHARMA LTD. annual revenue and profit?
For FY26, NATCO PHARMA LTD. reported full-year revenue of ₹4,045 cr and net profit of ₹1,419 cr, with EPS of ₹79.20.
How many quarterly results has NATCOPHARM declared recently?
Past results dates for NATCOPHARM will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 10 Sept 2026. For information only, not investment advice.
